Johnson & Johnson (JNJ) Earnings
Johnson & Johnson is expected to report next earnings on July 15, 2026 (in NaN days), with a consensus EPS estimate of $2.83. JNJ has beaten EPS estimates in 9 of its last 12 reported quarters (average surprise +1.4% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 14, 2026 | $2.68 | $2.70 | +0.7% | $24.1B | +1.9% |
| Jan 21, 2026 | $2.46 | $2.46 | +0.0% | $24.6B | +1.7% |
| Oct 14, 2025 | $2.76 | $2.80 | +1.4% | $24.0B | +1.0% |
| Jul 16, 2025 | $2.68 | $2.77 | +3.4% | $23.7B | +3.9% |
| Apr 15, 2025 | $2.58 | $2.77 | +7.4% | $21.9B | +1.6% |
| Jan 22, 2025 | $1.99 | $2.04 | +2.5% | $22.5B | +0.4% |
| Oct 15, 2024 | $2.21 | $2.42 | +9.5% | $22.5B | +1.3% |
| Jul 17, 2024 | $2.71 | $2.82 | +4.1% | $22.4B | +0.5% |
| Apr 16, 2024 | $2.64 | $2.71 | +2.7% | $21.4B | -0.1% |
| Jan 23, 2024 | $2.27 | $2.29 | +0.9% | $21.4B | +1.9% |
| Oct 17, 2023 | $2.52 | $2.66 | +5.6% | $21.4B | +7.7% |
| Jul 20, 2023 | $2.61 | $2.80 | +7.3% | $21.5B | -12.6% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 14, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Joaquin Duarte mentioned 2026 is a year of accelerated growth, with Q1 performance meeting or exceeding consensus and revenue guidance. He highlighted strong operational sales growth across key businesses, the strong portfolio and pipeline. Darren Snellgrove reviewed Q1 sales and P&L results. Joe Walk discussed cash and capital allocation, announced a dividend increase, and updated full-year 2026 guidance. Key operational highlights included growth in innovative medicine segments like oncology, immunology, neuroscience, and MedTech segments like cardiovascular, surgery, vision.
Guidance
Increased operational sales guidance to 5.9% - 6.9% range, midpoint $100.2 billion or 6.4%. Reported sales growth expected 6.5% - 7.5%, midpoint $100.8 billion or 7%. Maintaining adjusted pre-tax operating margin guidance to improve by at least 50 basis points. Adjusted operational earnings per share guidance increased by two cents to $11.30 - $11.50 range, midpoint $11.55 or 7.1% growth.
Segment performance
Innovative Medicine: Worldwide sales of $15.4 billion increased 7.4%, with oncology (e.g., Darzalex with 17.8% growth, Carvicti with 57.4% growth, etc.), immunology (Trenfaya with 64% growth, Icotide's launch), neuroscience (Spravato with 44.5% growth, CapLighter with $270 million sales) showing strong performance. MedTech: Worldwide sales of $8.6 billion increased 4.6%, with cardiovascular (electrophysiology 9.5% growth, Abiomed 14.4% growth, Shockwave 18.1% growth), surgery (progress on Otava robotic surgical system), vision (contact lenses 2.7% growth, surgical vision 6% growth, Technis intraocular lenses including Technis Pure-C approval) having growth in respective areas.
Risks & headwinds
Not explicitly detailed in the provided transcript regarding specific risks and operational failures beyond general mentions of risks and uncertainties in forward-looking statements related to actual results differing from projections, which can be found in SEC filings.
Analyst Q&A
Q: Terrence Flynn asked about positioning and reimbursement of Icotide.
A: Discussed Icotide's differentiated label, fast start, early patient uptake, and positioning as first-line systemic therapy.
Q: Larry Beagleson asked about MedTech end markets.
A: Stated Q1 played out as expected, balanced seasonality and execution, solid end markets with some procedural softness early but not material.
Q: Asad Haider asked about double-digit growth and BD.
A: Explained double-digit growth prospects from portfolio, pipeline, new launches, and separation of ortho, with BD being an important part but priority on portfolio and pipeline.
Q: Chris Schott asked about Icotide prescriptions and indication balance.
A: Said early on Icotide, new prescribers, and balanced potential in psoriasis and IBD.
Q: Shugun Singh asked about MedTech growth drivers.
A: Talked about Abiomed's growth from Impella data, Shockwave's market position and portfolio, and catalysts in surgery.
Q: Alexandria Hammond asked about Icotide's prescriber/patient education and Iconic Ascend trial.
A: Stated investments in Icotide, and will have more on direct-to-consumer.
Q: Joanne Wench asked about ophthalmology franchise.
A: Said vision had solid Q1, contact lens and surgical vision growth with seasonality, and excitement for new IOL launches.
Q: David Reisinger asked about JNJ4804 and M of A sales.
A: Talked about JNJ4804's role in IBD and phase II data, and M of A sales not disclosed.
Q: Matt Mixick asked about Inlexo's commercialization.
A: Explained Inlexo's performance in non-muscle invasive bladder cancer, J-code impact, and future plans with related products and go-to-market model